Intervention
Resveratrol
ClinicalTrials.gov intervention label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 30 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
30 shownType 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1NCT04449198 · 2020-10-14
RECRUITINGResveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 DiabetesNCT07569744 · 2026-05-01
COMPLETEDAssessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With NeuropathyNCT06131918 · 2023-01-09
COMPLETEDEffect of Resveratrol and Pharmacist Intervention on Diabetes Mellitus and Its Neuropathic ComplicationNCT05172947 · 2021-12-05
COMPLETEDImproving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary DiseaseNCT03819517 · 2019-07-01
COMPLETEDResveratrol and Vascular Function in CKDNCT03597568 · 2019-01-01
COMPLETEDResveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to BedsideNCT01914081 · 2018-10-09
UNKNOWNEstrogen and DiabetesNCT03436992 · 2018-04-17
COMPLETEDThe Effects of Resveratrol Supplementation on Cognition, Cerebral Blood Flow, Microbiota and Systemic Inflammation.NCT03448094 · 2018-02-06
COMPLETEDEvaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart FailureNCT03525379 · 2017-10-26
COMPLETEDEffect of Administration of Resveratrol on Glycemic Variability in Individuals With Type 2 Diabetes MellitusNCT02549924 · 2016-09-01
TERMINATEDResveratrol's Effects in Diabetic NephropathyNCT02704494 · 2016-03-01
COMPLETEDResveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight AdolescentsNCT02216552 · 2015-08-01
COMPLETEDResveratrol and Cardiovascular Health in the ElderlyNCT01842399 · 2015-07-14
TERMINATEDResveratrol In Chronic Obstructive Pulmonary Disease (COPD) Patients (CARMENS-trial)NCT02245932 · 2015-01-01
COMPLETEDCan Resveratrol Improve Insulin Sensitivity and Preserve Beta Cell Function Following Gestational Diabetes?NCT01997762 · 2014-05-01
UNKNOWNResveratrol Stimulates Insulin Sensitivity in Subjects With Obesity and Insulin ResistanceNCT06961279 · 2013-09-15
COMPLETEDShort-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass SurgeryNCT01826279 · 2013-05-01
UNKNOWNEffects of Resveratrol on Endothelial Function in Type 2 Diabetes MellitusNCT01881347 · 2013-01-01
COMPLETEDResveratrol and the Metabolic SyndromeNCT01714102 · 2012-10-01
COMPLETEDResveratrol for Alzheimer's DiseaseNCT01504854 · 2012-05-01
COMPLETEDEffect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin SecretionNCT02114892 · 2012-04-01
COMPLETEDResveratrol-Leucine Metabolite Synergy in Pre-diabetesNCT01593605 · 2012-02-01
COMPLETEDLong-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver DiseaseNCT01446276 · 2011-11-01
COMPLETEDRegulation of Intestinal and Hepatic Lipoprotein Secretion by ResveratrolNCT01451918 · 2011-10-01
COMPLETEDLong-term Investigation of Resveratrol in ObesityNCT01412645 · 2011-08-01
COMPLETEDPotential Beneficial Effects of ResveratrolNCT01150955 · 2010-10-01
COMPLETEDPilot Study Of The Effects Of Resveratrol On Endothelial Function In Subjects With Type 2 Diabetes MellitusNCT01038089 · 2010-01-01
COMPLETEDEffects of High-Dose Resveratrol in Non-Diabetic Obese MalesNCT02247596 · 2009-07-01
COMPLETEDEffect of Resveratrol on Age-related Insulin Resistance and Inflammation in HumansNCT01354977 · 2008-03-01
COMPLETEDCommon conditions
Obesity7Type 2 Diabetes Mellitus4Insulin Resistance3METABOLIC SYNDROME3Endothelial Dysfunction2Alzheimer's Disease1Cerebral Blood Flow1Chronic Kidney Diseases1Chronic Obstructive Pulmonary Disease1Cognitive Function and Mood1Congestive Heart Failure Chronic1Diabetes1Diabetes Mellitus1Diabetes Mellitus, Type 11Diabetic Nephropathy1Diabetic Neuropathies1Dilated Cardiomyopathy1Dyslipidaemia1Gestational Diabetes1Gut Microbiota1Hypertension1Impaired Glucose Tolerance1Inflammation1Insulin Sensitivity1Metabolic Syndrome X1
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
obesity disorder7type 2 diabetes mellitus5abdominal obesity-metabolic syndrome3diabetes mellitus2metabolic dysfunction-associated steatotic liver disease2Alzheimer disease1chronic obstructive pulmonary disease1diabetic kidney disease1dilated cardiomyopathy1gestational diabetes1metabolic syndrome X1osteoporosis1type 1 diabetes mellitus1
Leading sponsors
University of Aarhus
4
Augusta University
2
Boston University
2
University of Guadalajara
2
University of Manitoba
2
Albert Einstein College of Medicine
1
Alzheimer's Disease Cooperative Study (ADCS)
1
Diana Jalal
1
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
1
Khoo Teck Puat Hospital
1
Khyber Medical University Peshawar
1
Maastricht University Medical Center
1
National Institute on Aging (NIA)
1
Northumbria University
1
Rockefeller University
1
Trial status mix
COMPLETED24
UNKNOWN3
TERMINATED2
RECRUITING1
Phase mix
NA15
PHASE210
EARLY_PHASE13
PHASE32
PHASE11
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.